The global in vivo CRO market is witnessing robust growth due to increasing pharmaceutical and biotechnology research, rising outsourcing of preclinical studies, and growing demand for efficient drug development services. The global in vivo CRO market size was valued at USD 5.36 billion in 2025 and is projected to grow from USD 5.8 billion in 2026 to USD 10.89 billion by 2034, registering a CAGR of 8.2% during the forecast period (2026–2034).

In vivo contract research organizations (CROs) provide preclinical testing services that evaluate the safety, efficacy, and pharmacological properties of drug candidates using animal models before clinical trials. These services are essential for pharmaceutical, biotechnology, and medical device companies seeking to accelerate drug development while reducing operational costs. Increasing investments in research and development, advancements in preclinical testing technologies, and the growing complexity of drug discovery are expected to drive market expansion throughout the forecast period.

Market Drivers

One of the primary factors driving the in vivo CRO market is the increasing outsourcing of preclinical research by pharmaceutical and biotechnology companies. Drug developers are increasingly partnering with specialized CROs to reduce development costs, access advanced research expertise, and accelerate the drug approval process. Outsourcing also enables companies to focus on their core competencies while improving operational efficiency.

Another significant growth driver is the rising prevalence of chronic diseases such as cancer, neurological disorders, diabetes, and autoimmune diseases. The growing need for innovative therapies has increased investments in drug discovery and preclinical research, creating strong demand for in vivo CRO services. Oncology remains one of the largest therapeutic areas for in vivo studies due to the continuous development of novel cancer treatments.

Technological advancements in preclinical research are also contributing to market growth. The adoption of advanced animal models, imaging technologies, artificial intelligence, digital pathology, and automated laboratory systems has significantly improved research accuracy, study efficiency, and regulatory compliance. These innovations are enabling CROs to deliver high-quality preclinical data within shorter timelines.

Furthermore, increasing research and development investments by pharmaceutical companies, government organizations, and academic institutions are creating new growth opportunities for market participants. Rising demand for biologics, gene therapies, and personalized medicines continues to expand the need for specialized in vivo testing services.

Market Challenges

Despite favorable growth prospects, the in vivo CRO market faces several challenges.

One of the major restraints is the stringent regulatory framework governing animal testing and preclinical research. Compliance with international ethical standards and Good Laboratory Practice (GLP) regulations increases operational complexity and costs for CROs.

Another challenge is the growing emphasis on reducing animal testing through alternative in vitro models and computational research methods. Regulatory agencies and research organizations are increasingly encouraging the adoption of alternative testing approaches where feasible.

Additionally, maintaining highly specialized research facilities and recruiting skilled scientific professionals require substantial investments, which may create barriers for smaller contract research organizations.

Market Segmentation

By Model Type

• Rodent
• Non-Rodent

The rodent segment accounts for the largest market share due to the widespread use of mice and rats in preclinical studies. Rodent models offer strong genetic similarities to humans, lower research costs, and well-established disease models, making them the preferred choice for pharmaceutical research.

By Study Type

• GLP Toxicology
• Non-GLP

The GLP toxicology segment dominates the market owing to increasing regulatory requirements for standardized safety evaluations before clinical trials. Pharmaceutical companies rely on GLP-compliant studies to support regulatory submissions and ensure patient safety.

By Indication

• Oncology
• CNS Conditions
• Diabetes
• Obesity
• Autoimmune/Inflammatory Conditions
• Pain Management
• Others

The oncology segment holds the largest market share due to increasing global cancer prevalence and the growing number of oncology drug development programs requiring extensive preclinical evaluation using animal models.

Regional Insights

North America

North America dominates the global in vivo CRO market due to its well-established pharmaceutical industry, advanced research infrastructure, increasing government funding for biomedical research, and the presence of leading contract research organizations. The United States continues to drive regional market growth through substantial investments in drug development and biotechnology innovation.

Europe

Europe represents a significant market supported by increasing pharmaceutical research activities, favorable regulatory frameworks, expanding biotechnology sectors, and growing collaboration between research institutions and CROs.

Asia-Pacific

Asia-Pacific is expected to witness the fastest growth during the forecast period owing to expanding pharmaceutical manufacturing, increasing clinical and preclinical research activities, lower research costs, and growing investments in biotechnology across China, India, Japan, South Korea, and Singapore.

Latin America, Middle East, and Africa

These regions are emerging markets driven by improving healthcare infrastructure, increasing pharmaceutical investments, expanding biomedical research capabilities, and growing outsourcing of preclinical studies by global pharmaceutical companies.

Key Players Analysis

The in vivo CRO market is highly competitive, with leading companies focusing on expanding research capabilities, strengthening regulatory compliance, adopting advanced laboratory technologies, and forming strategic partnerships with pharmaceutical and biotechnology companies. Continuous investments in research infrastructure and specialized preclinical services are helping companies strengthen their global market position.

Major companies operating in the market include:

• Charles River Laboratories International, Inc.
• Labcorp Drug Development
• IQVIA Inc.
• Eurofins Scientific SE
• WuXi AppTec Co., Ltd.
• Medpace Holdings, Inc.
• Evotec SE
• Syneos Health, Inc.
• Pharmaron Beijing Co., Ltd.
• Crown Bioscience Inc.

These companies continue expanding their service portfolios, investing in advanced preclinical research technologies, and strengthening global operations to meet the growing demand for outsourced drug discovery and development services.

For Detailed Insights, Visit:

https://straitsresearch.com/report/in-vivo-cro-market

About Us

Straits Research is a leading market research and intelligence organization specializing in research, analytics, and advisory services. The company provides comprehensive market reports, industry insights, and strategic business intelligence across multiple industries, helping organizations identify growth opportunities and make informed business decisions.

Contact Us

Email: sales@straitsresearch.com

Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)